Publications by authors named "Paola Robayo"

Article Synopsis
  • SF3B1 mutations are common in cancer but lack directed treatments. Recent trials of XPO1 inhibitors in high-risk myelodysplastic neoplasms (MDS) found that patients with these mutations respond better to treatment.
  • The study explores how these mutations affect RNA behavior when XPO1 is inhibited, leading to altered splicing and activation of apoptotic pathways in the mutant cells.
  • Researchers identified that combining eltanexor (an XPO1 inhibitor) with venetoclax (a BCL2 inhibitor) effectively targets SF3B1 mutant cells while minimizing toxicity, paving the way for new treatment strategies for high-risk MDS.
View Article and Find Full Text PDF

Mitochondria's role as engines and beacons of metabolism and determinants of cellular health is being redefined through their therapeutic application as "Living Drugs" (LDs). Artificial mitochondrial transfer/transplant (AMT/T), encompassing various techniques to modify, enrich, or restore mitochondria in cells and tissues, is revolutionizing acellular therapies and the future of medicine. This article proposes a necessary definition for LDs within the Advanced Therapeutic Medicinal Products (ATMPs) framework.

View Article and Find Full Text PDF

Early-stage professionals (ESPs) and senior scientists who want to transition from academia to the industry need support to develop new skills and know-how to endeavor this challenge. However, this topic is significantly underserved in the field of cell and gene therapy, slowing down ESPs' potential to make this step. The authors of this article, members of the ESPs in the South and Central America Subcommittee at the International Society for Cell and Gene Therapy, propose the concept of "scientific venturing," which stands for the process by which scientists become entrepreneurs or part of a company.

View Article and Find Full Text PDF

Prion diseases encompass a group of incurable neurodegenerative disorders that occur due to the misfolding and aggregation of infectious proteins. The most well-known prion diseases are Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (also known as mad cow disease), and kuru. It is estimated that around 1-2 persons per million worldwide are affected annually by prion disorders.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is a leading neurodegenerative pathology associated with aging worldwide. It is estimated that AD prevalence will increase from 5.8 million people today to 13.

View Article and Find Full Text PDF

Parkinson's disease (PD) is the most common neurodegenerative movement disorder, worldwide. PD neuro-energetically affects the extrapyramidal system, by the progressive loss of striatal dopaminergic neurons in the substantia nigra pars compacta, leading to motor impairment. During the progression of PD, there will be an increase in mitochondrial dysfunction, reactive oxygen species (ROS), stress and accumulation of α-synuclein in neurons.

View Article and Find Full Text PDF

Around two-thirds of women who are of reproductive age use some type of contraception. Two of the most effective long-acting reversible contraceptives (LARC) are the intrauterine device (IUD) and the subdermal contraceptive implant (SCI). Despite their effectiveness, women often report abnormal uterine bleeding as the reason for discontinuation.

View Article and Find Full Text PDF